• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    11/12/24 9:34:18 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WVE alert in real time by email
    SC 13G/A 1 p24-3046sc13ga.htm

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*, **
     

    Wave Life Sciences Ltd.

    (Name of Issuer)
     

    Ordinary Shares, no par value

    (Title of Class of Securities)
     

    Y95308105

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    ** The original Schedule 13G and any amendment thereto filed with the Securities and Exchange Commission with respect to the Ordinary Shares held by the Reporting Persons (as defined in Item 2(a) hereof) prior to the date hereof was filed by Adage Capital Partners GP, L.L.C. (CIK 0001165408), which is no longer a Reporting Person with respect to the Ordinary Shares held by the Reporting Persons.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. Y9530810513G/APage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    9,703,351

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    9,703,351

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,703,351

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.66%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

    CUSIP No. Y9530810513G/APage 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    9,703,351

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    9,703,351

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,703,351

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.66%

    12

    TYPE OF REPORTING PERSON

    IN; HC

             

     

     

     

     

    CUSIP No. Y9530810513G/APage 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    9,703,351

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    9,703,351

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,703,351

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.66%

    12

    TYPE OF REPORTING PERSON

    IN; HC

             

     

     

     

     

    CUSIP No. Y9530810513G/APage 5 of 8 Pages

     

     

    Item 1(a). NAME OF ISSUER:
      The name of the issuer is Wave Life Sciences Ltd. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
      The Company’s principal executive offices are located at 7 Straits View #12-00, Marina One, East Tower, Singapore 018936.

     

    Item 2(a). NAME OF PERSON FILING:
      This statement is filed by:
       
      (i) Adage Capital Management, L.P., a Delaware limited partnership (“ACM”), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership (“ACP”), with respect to the Ordinary Shares directly held by ACP;
       
      (ii) Robert Atchinson (“Mr. Atchinson”), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA”), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP”), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company (“ACPLLC”), general partner of ACM, with respect to the Ordinary Shares directly held by ACP; and
       
      (iii) Phillip Gross (“Mr. Gross”), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the Ordinary Shares directly held by ACP.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP:
      ACM is a limited partnership organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
      Ordinary Shares, no par value (the “Ordinary Shares”).

     

    Item 2(e). CUSIP NUMBER:
      Y95308105

     

     

    CUSIP No. Y9530810513G/APage 6 of 8 Pages

     

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) þ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) þ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: Not applicable.

     

    Item 4. OWNERSHIP:
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentage set forth in this Schedule 13G/A is calculated based upon 145,604,290 Ordinary Shares, reported to be outstanding in the Company’s Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on September 27, 2024, after giving effect to the completion of the offering, as described therein.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
      See Item 2(a).

     

     

    CUSIP No. Y9530810513G/APage 7 of 8 Pages

     

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON:
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
      Not applicable.

     

    Item 10. CERTIFICATIO:N  
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. Y9530810513G/APage 8 of 8 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 12, 2024

     

      ADAGE CAPITAL MANAGEMENT, L.P.
      By: Adage Capital Partners LLC,
      its general partner
       
      /s/ Robert Atchinson
      Name:  Robert Atchinson
      Title: Managing Member
       
      /s/ Robert Atchinson
      ROBERT ATCHINSON, individually
       
      /s/ Phillip Gross
      PHILLIP GROSS, individually

     

    Get the next $WVE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WVE

    DatePrice TargetRatingAnalyst
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/8/2025$18.00Outperform
    Wedbush
    2/25/2025$26.00Buy
    Jefferies
    10/16/2024$22.00Outperform → Strong Buy
    Raymond James
    9/27/2024$10.00 → $13.00Overweight
    JP Morgan
    9/19/2024$11.00Buy
    B. Riley Securities
    9/9/2024$10.00Overweight
    JP Morgan
    5/15/2024$11.00Overweight
    Wells Fargo
    More analyst ratings

    $WVE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Wave Life Sciences Ltd.

      10-Q - Wave Life Sciences Ltd. (0001631574) (Filer)

      5/8/25 7:45:16 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Wave Life Sciences Ltd.

      8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

      5/8/25 7:36:06 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Wave Life Sciences Ltd.

      10-K/A - Wave Life Sciences Ltd. (0001631574) (Filer)

      4/29/25 5:00:21 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

      Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement i

      5/8/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call by di

      5/1/25 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

      Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA First-ever demonstration of substantial improvements in muscle health with exon skipping – statistically significant reduction in fibrosis driven by decreases in inflammation and necrosis, coupled with transition from regenerative to mature muscle; decreases in creatine kinase and circulating inflammatory biomarkers Dystrophin expression stabilized between 24 and 48 weeks and averaged 7.8%, with 88% o

      3/26/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      11/12/24 4:30:35 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      11/12/24 9:34:18 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Wave Life Sciences Ltd.

      SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      10/1/24 5:47:15 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Gsk Plc bought $22,335,440 worth of Ordinary Shares (2,791,930 units at $8.00) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      10/1/24 5:54:39 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gsk Plc bought $16,500,000 worth of Ordinary Shares (3,300,000 units at $5.00) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      1/30/24 4:39:08 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ra Capital Management, L.P. bought $5,000,000 worth of shares (1,000,000 units at $5.00) (SEC Form 4) (Amendment)

      4/A - Wave Life Sciences Ltd. (0001631574) (Issuer)

      1/17/24 7:06:57 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $WVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Wave Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $10.00

      4/29/25 8:13:21 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Wave Life Sciences with a new price target

      Wedbush initiated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $18.00

      4/8/25 9:33:34 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Wave Life Sciences with a new price target

      Jefferies initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $26.00

      2/25/25 7:15:48 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Henry Christian O sold $102,574 worth of Ordinary Shares (10,500 units at $9.77) and exercised 10,500 units of Ordinary Shares at a strike of $9.13 (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/21/25 9:00:05 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Bolno Paul exercised 169,025 units of Ordinary Shares at a strike of $2.48 and sold $1,617,569 worth of Ordinary Shares (169,025 units at $9.57) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/7/25 9:05:03 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Verdine Gregory L. exercised 266,402 units of Ordinary Shares at a strike of $2.48, increasing direct ownership by 577% to 312,517 units (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/7/25 9:00:05 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Leadership Updates

    Live Leadership Updates

    See more
    • Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

      CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK

      5/9/24 7:00:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors

      BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development

      3/21/22 7:05:00 AM ET
      $ATHA
      $WVE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer

      CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human Resources Officer (CHRO). As CHRO, Mr. Rosin will provide strategic enterprise counsel and leadership, both as a member of Wave’s Executive Team and by leading the human resources function. “Jonathan is an accomplished leader with the breadth of human resources experience necessary to help guide Wave as we prepare to support five programs in clinical trials in 2021, as well as advance a robust precl

      12/2/20 8:00:00 AM ET
      $SNY
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Financials

    Live finance-specific insights

    See more
    • Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

      Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement i

      5/8/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call by di

      5/1/25 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

      Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA First-ever demonstration of substantial improvements in muscle health with exon skipping – statistically significant reduction in fibrosis driven by decreases in inflammation and necrosis, coupled with transition from regenerative to mature muscle; decreases in creatine kinase and circulating inflammatory biomarkers Dystrophin expression stabilized between 24 and 48 weeks and averaged 7.8%, with 88% o

      3/26/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care